1392193-72-4

Upstream product

• 156996-01-9 13-(β-D-glucopyranosyl)-6-N-methylarcyriaflavin C 
• 174402-48-3 12,13-dihydro-2,10-dibenzyloxy-13-(β-D-2,3,4,6-tetra-O-benzylglucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-6-methyl-5,7(6H)-dione 
• 4291-69-4 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 
• 1390624-75-5 C₁₁H₂₂N₂O₄ 
• 1390624-74-4 C₁₁H₂₀N₂O₄ 
• 1390624-59-5 C₁₂H₂₀O₆ 
• 174402-49-4 C₂₆H₂₀N₂O₁₀ 
• 4291-68-3 1-chloro-2,3,4,6-tetra-O-benzyl-D-glucopyranoside 

Relevant academic research and scientific papers

Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety

Glycosylated indolocarbazoles related to the antibiotic rebeccamycin represent an important class of antitumour drugs. In the course of our structure-activity relationship studies, new rebeccamycin analogues modified at the imide moiety were synthesised. The antiproliferative activity of the compounds was evaluated on three human cancer cell lines, A2780 (ovarian cancer), H460 (lung cancer), and GLC4 (small-cell lung cancer). The in vitro cytotoxicity of compounds 2 and 4, characterised respectively by a 1,3-dioxolan and (1,3-dioxolan-4-yl)methylene groups linked to the imide moiety, was higher than the reference compound, edotecarin. The effect of compound 2 in inducing tumour regression in the A2780 xenograft model was also investigated.